# ZG006

Source: https://onco.cc/drugs/zg006/  
OnCo record `zg006` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ZG006 is an experimental investigational agent whose form is not stated in the registry from Suzhou Zelgen Biopharmaceuticals in phase 3 trials for non-small-cell lung cancer and neuroendocrine tumours, with its target not yet stated publicly.

## Summary

ZG006 is an investigational agent whose form is not stated in the registry developed by Suzhou Zelgen Biopharmaceuticals. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: ZG006 will be administered as an intravenous (IV) infusion. It is the investigational product in 6 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07189455 (Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer), in non-small-cell lung cancer and neuroendocrine tumours. The largest, NCT07189455, plans to enrol 420 participants with primary completion expected 2028-10. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: trispecific T-cell engager antibody (DLL3 x DLL3 x CD3, per the sponsor's pipeline page; form not stated in the registry record)
- Mechanism: Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.

## Sources

- ClinicalTrials.gov: trials of ZG006: https://clinicaltrials.gov/search?intr=ZG006

## Connected records

- cancers: [Extrapulmonary neuroendocrine carcinoma](https://onco.cc/cancers/extrapulmonary-nec/), [Neuroendocrine tumours](https://onco.cc/cancers/neuroendocrine/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- companies: [Suzhou Zelgen Biopharmaceuticals](https://onco.cc/companies/zelgen/)
- trials: [Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in P](https://onco.cc/trials/nct06283719/), [Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.](https://onco.cc/trials/nct06440057/), [Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer](https://onco.cc/trials/nct07189455/), [Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma](https://onco.cc/trials/nct05978284/), [Study of ZGGS34 in Participants With Advanced Solid Tumors](https://onco.cc/trials/nct07258121/), [ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma](https://onco.cc/trials/nct07038096/)
- drugs: [Obrixtamig](https://onco.cc/drugs/obrixtamig/)

---
JSON: https://onco.cc/api/v1/entities/zg006.json